Selecting First-line Therapy for Advanced UC: Chemotherapy vs Immunotherapy

Experts provide their thoughts on key data in breast, gynecologic, renal cell, urothelial, lung, hepatobiliary, and skin cancers presented at the 2022 ESMO Congress, from Clinical Care Options (CCO)

Nicoletta Colombo, MD Robert Motzer, MD Sapna P. Patel, MD David Planchard, MD, PhD Elizabeth R. Plimack, MD, MS Rachna Shroff, MD, MS Sara Tolaney, MD, MPH Physicians: maximum of 1.25 AMA PRA Category 1 Credits™ Released: November 14, 2022 Expired: November 13, 2023

Downloadable clinical resource with practical guidance on preventative care plans for transgender patients, from Clinical Care Options (CCO)

Nelson F. Sanchez, MD
Program Director Released: October 7, 2022

Download this expert slideset on strategies for developing compassionate care plans with transgender patients based on their current anatomy

Lauren Radziejewski, DNP Released: October 4, 2022

Phase III COSMIC-313: addition of cabozantinib to nivolumab plus ipilimumab in previously untreated patients with IMDC intermediate- or poor-risk advanced RCC, presented at ESMO 2022 and reported by Clinical Care Options (CCO)